Management of Percutaneous Coronary Interventions Complications

Saturday, March 8, 2025

4:49 PM – 4:57 PM ET

Speaker(s)

UR

Umamahesh C. Rangasetty, MD

Interventional cardiologist
University of Texas Medical branch at Galveston, Texas, United States

Disclosure(s): Abbott Cardiovascular Systems: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Edwards, Medtronic, Boston Scientific: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Moderna: Stock-publicly held company (excluding mutual/index funds) (Terminated); Pfizer: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Philips-Spectranetics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave Medical: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Disclosure(s):

Umamahesh C. Rangasetty, MD: Abbott Cardiovascular Systems: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Edwards, Medtronic, Boston Scientific: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Moderna: Stock-publicly held company (excluding mutual/index funds) (Terminated); Pfizer: Stock-publicly held company (excluding mutual/index funds) (Ongoing); Philips-Spectranetics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Shockwave Medical: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)